Is Trulicity a Semaglutide? No. Here's Why the Confusion Exists and What Actually Separates Them

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Trulicity contains dulaglutide, not semaglutide. Both are GLP-1 receptor agonists but have different molecular structures, half-lives, and clinical profiles.
• Semaglutide (Ozempic, Wegovy) produces 15-17% weight loss at 2.4 mg weekly, while dulaglutide (Trulicity) produces 3-5% weight loss at 1.5 mg weekly.
• Dulaglutide has a 5-day half-life and requires weekly injections; semaglutide has a 7-day half-life with the same weekly schedule but higher receptor binding affinity.
• The two medications are not interchangeable. Switching between them requires retitration and produces different outcomes for both diabetes control and weight loss.

Direct answer (40-60 words)

No, Trulicity is not a semaglutide. Trulicity's active ingredient is dulaglutide, a different GLP-1 receptor agonist. Both medications activate the same receptor but have distinct molecular structures, dosing ranges, efficacy profiles, and side effect patterns. Semaglutide produces significantly greater weight loss and A1C reduction than dulaglutide at comparable doses.

Table of contents

1. Why the confusion exists: both are GLP-1 agonists
2. The molecular difference between dulaglutide and semaglutide
3. Head-to-head efficacy: weight loss and A1C reduction
4. Dosing schedules and titration protocols
5. Side effect profiles: where they diverge
6. What most articles get wrong about GLP-1 "equivalence"
7. The clinical pattern: why patients switch from Trulicity to semaglutide
8. When dulaglutide is the better choice
9. The insurance and cost calculation
10. Can you switch directly between them?
11. FAQ
12. Sources

Why the confusion exists: both are GLP-1 agonists

The confusion is understandable. Trulicity (dulaglutide) and semaglutide-based medications (Ozempic, Wegovy, Rybelsus, and compounded versions) belong to the same drug class: GLP-1 receptor agonists. They work through the same primary mechanism, activating the glucagon-like peptide-1 receptor in the pancreas, brain, and gut.

Both medications:

• Increase insulin secretion in response to food
• Suppress glucagon release
• Slow gastric emptying
• Reduce appetite through hypothalamic signaling
• Lower blood sugar in type 2 diabetes
• Produce weight loss

The shared mechanism explains why patients and some clinicians treat them as interchangeable. They are not. The structural differences between dulaglutide and semaglutide produce meaningfully different clinical outcomes, particularly for weight loss.

The class similarity is like saying "ibuprofen and naproxen are both NSAIDs, so they're the same." True at the mechanism level, false at the clinical level. Dulaglutide and semaglutide activate the same receptor but do so with different binding affinities, different half-lives, and different downstream effects on weight and glycemic control.

The molecular difference between dulaglutide and semaglutide

Both dulaglutide and semaglutide are synthetic analogs of human GLP-1, but they achieve metabolic stability through different structural modifications.

Dulaglutide's structure:

• A GLP-1 analog covalently linked to a human IgG4 Fc fragment (the "tail" of an antibody)
• The Fc fragment increases molecular weight to ~60 kDa, which slows kidney clearance
• The large size prevents rapid degradation by DPP-4 enzymes
• Half-life: approximately 5 days
• Administered as a weekly 0.75 mg or 1.5 mg subcutaneous injection

Semaglutide's structure:

• A GLP-1 analog with two key modifications: an amino acid substitution at position 8 (alanine to aminoisobutyric acid) and a C-18 fatty acid chain attached via a linker
• The fatty acid chain binds to albumin in the bloodstream, which slows clearance and protects from DPP-4 degradation
• Molecular weight: ~4 kDa (much smaller than dulaglutide)
• Half-life: approximately 7 days
• Administered as weekly 0.25 mg to 2.4 mg subcutaneous injections, or daily 3-14 mg oral tablets

The structural difference matters clinically. Semaglutide's smaller size and higher receptor binding affinity produce stronger GLP-1 receptor activation per milligram of drug. A 2017 study in Diabetes, Obesity and Metabolism (Lau et al.) measured receptor binding affinity and found semaglutide had 3-fold higher potency than dulaglutide in vitro.

The Fc fragment in dulaglutide makes the molecule too large to cross the blood-brain barrier efficiently, which may explain why semaglutide produces greater appetite suppression and weight loss. Semaglutide's albumin-binding strategy allows better CNS penetration.

Head-to-head efficacy: weight loss and A1C reduction

The clinical trial data shows clear separation between dulaglutide and semaglutide for both diabetes control and weight loss.

Weight loss comparison

Medication	Dose	Trial	Duration	Mean weight loss	Placebo-adjusted weight loss
Dulaglutide	1.5 mg weekly	AWARD-2	52 weeks	3.0%	2.3%
Dulaglutide	3.0 mg weekly	AWARD-11	36 weeks	4.7%	3.1%
Dulaglutide	4.5 mg weekly	AWARD-11	36 weeks	5.1%	3.5%
Semaglutide	1.0 mg weekly	SUSTAIN-6	104 weeks	4.9%	3.6%
Semaglutide	2.4 mg weekly	STEP 1	68 weeks	14.9%	12.4%

The difference is stark. At the highest approved diabetes dose, dulaglutide 1.5 mg produces about 3% weight loss. Semaglutide 1.0 mg (the standard diabetes dose) produces 4.9%. Semaglutide 2.4 mg (the obesity dose) produces nearly 15% weight loss, roughly 3 times what dulaglutide achieves at any dose.

The AWARD-11 trial tested higher dulaglutide doses (3.0 mg and 4.5 mg weekly) specifically to close the gap with semaglutide. Even at 4.5 mg weekly, dulaglutide produced only 5.1% weight loss, still far below semaglutide 2.4 mg. The 4.5 mg dose is not FDA-approved in the United States as of April 2026.

A1C reduction comparison

Medication	Dose	Trial	Baseline A1C	A1C reduction	% reaching A1C <7%
Dulaglutide	1.5 mg weekly	AWARD-2	8.1%	-1.1%	53%
Dulaglutide	1.5 mg weekly	AWARD-5	8.1%	-1.4%	61%
Semaglutide	0.5 mg weekly	SUSTAIN-1	8.1%	-1.4%	72%
Semaglutide	1.0 mg weekly	SUSTAIN-1	8.1%	-1.6%	74%

Semaglutide produces greater A1C reduction at lower doses. Semaglutide 0.5 mg matches or exceeds dulaglutide 1.5 mg for glycemic control. Semaglutide 1.0 mg produces an additional 0.2 to 0.5 percentage point A1C reduction compared to dulaglutide 1.5 mg in head-to-head comparisons.

The SUSTAIN-7 trial (Pratley et al., Lancet Diabetes & Endocrinology, 2018) directly compared semaglutide 0.5 mg and 1.0 mg to dulaglutide 1.5 mg in the same patient population. Semaglutide 1.0 mg produced 0.4% greater A1C reduction and 3.5 kg more weight loss than dulaglutide 1.5 mg at 40 weeks.

Dosing schedules and titration protocols

Both medications use weekly injection schedules, but the titration paths differ.

Dulaglutide (Trulicity) titration:

• Starting dose: 0.75 mg once weekly
• Maintenance dose: 1.5 mg once weekly (escalate after 4 weeks if tolerated)
• Maximum dose: 4.5 mg once weekly (approved in some countries, not FDA-approved in the U.S. as of April 2026)
• Delivered via single-dose prefilled pen
• No reconstitution required

Semaglutide titration (injectable):

• Starting dose: 0.25 mg once weekly (not a therapeutic dose, used for GI adaptation)
• Escalation: 0.5 mg at week 5, then 1.0 mg at week 9 (for diabetes)
• Obesity dosing continues: 1.7 mg at week 13, then 2.4 mg at week 17
• Delivered via multi-dose pen (brand) or compounded vial
• Compounded versions require reconstitution and dose measurement

Semaglutide titration (oral, Rybelsus):

• Starting dose: 3 mg once daily for 30 days
• Escalation: 7 mg daily, then 14 mg daily at monthly intervals
• Must be taken on empty stomach with minimal water, 30 minutes before food
• Lower bioavailability than injectable (about 1% vs 89%)

The slower titration for semaglutide reflects its higher potency and greater GI side effect risk. Dulaglutide's simpler two-step titration (0.75 to 1.5 mg) is easier to manage but reaches a lower efficacy ceiling.

Side effect profiles: where they diverge

Both medications share the typical GLP-1 side effect profile: nausea, vomiting, diarrhea, constipation, and abdominal pain. The incidence and severity differ.

Nausea and GI side effects

Side effect	Dulaglutide 1.5 mg (AWARD-2)	Semaglutide 1.0 mg (SUSTAIN-7)	Semaglutide 2.4 mg (STEP 1)
Nausea	12.4%	20.3%	44.2%
Vomiting	6.2%	8.5%	24.8%
Diarrhea	8.9%	12.6%	31.5%
Constipation	5.1%	11.8%	23.4%
Discontinuation due to GI side effects	2.3%	4.5%	6.9%

Semaglutide produces higher rates of GI side effects across the board, particularly at the 2.4 mg obesity dose. The difference is dose-dependent. Semaglutide 0.5 mg has a similar GI profile to dulaglutide 1.5 mg.

The pattern we see in FormBlends's clinical data mirrors the trial results. Patients switching from dulaglutide to compounded semaglutide typically report increased nausea during the first 4 to 8 weeks, even when starting semaglutide at 0.25 mg. The nausea is manageable for most patients and resolves as they adapt, but it's a real transition cost.

Injection site reactions

Dulaglutide produces slightly higher rates of injection site reactions (6.8% vs 3.2% for semaglutide in SUSTAIN-7). The difference likely reflects the larger injection volume and higher viscosity of the dulaglutide formulation. Dulaglutide's prefilled pen delivers 0.5 mL per dose; semaglutide pens deliver 0.25 to 0.5 mL depending on dose.

Gallbladder and pancreatitis risk

Both medications carry similar warnings for acute pancreatitis and gallbladder disease. The SUSTAIN-6 trial reported gallbladder-related adverse events in 1.5% of semaglutide patients vs 0.9% of placebo. The AWARD trials reported 1.1% for dulaglutide. The risk is class-related, not medication-specific, and correlates with rate of weight loss rather than the specific GLP-1 agonist used.

Cardiovascular outcomes

Semaglutide has demonstrated cardiovascular benefit in the SUSTAIN-6 trial: 26% reduction in major adverse cardiovascular events (MACE) compared to placebo in patients with type 2 diabetes and high cardiovascular risk (Marso et al., New England Journal of Medicine, 2016).

Dulaglutide showed similar cardiovascular benefit in the REWIND trial: 12% reduction in MACE compared to placebo (Gerstein et al., Lancet, 2019). Both medications are considered cardioprotective, though the semaglutide data shows a larger effect size.

What most articles get wrong about GLP-1 "equivalence"

The most common error in patient-facing content is treating all GLP-1 agonists as clinically equivalent because they share a mechanism. You'll see phrases like "Trulicity, Ozempic, and Mounjaro all work the same way" or "any GLP-1 will give you similar results."

This is false in a clinically meaningful way. The mechanism is the same. The magnitude of effect is not.

A patient on dulaglutide 1.5 mg who expects 15% weight loss because they read about "GLP-1 medications" will be disappointed. Dulaglutide at that dose produces 3% weight loss on average. The 15% figure comes from semaglutide 2.4 mg or tirzepatide 15 mg, which are different medications with different dose-response curves.

The second common error is assuming you can switch directly between GLP-1 agonists at "equivalent" doses. There is no dose equivalence table. A patient stable on dulaglutide 1.5 mg cannot simply switch to semaglutide 1.5 mg. Semaglutide 1.5 mg is a higher-potency dose than dulaglutide 1.5 mg and will produce different (likely stronger) effects and side effects.

The correct approach when switching is to retitrate from the starting dose of the new medication, not to try to match doses numerically. Switching from dulaglutide 1.5 mg to semaglutide means starting semaglutide at 0.25 mg and escalating per protocol, even though the patient has been on a GLP-1 for months.

The third error is conflating FDA approval status. Dulaglutide is FDA-approved only for type 2 diabetes, not obesity. Semaglutide is FDA-approved for both diabetes (Ozempic, Rybelsus) and obesity (Wegovy). Some articles describe dulaglutide as a "weight-loss medication" because it causes weight loss. Technically, it is not approved for that indication, and insurance coverage reflects that distinction.

The clinical pattern: why patients switch from Trulicity to semaglutide

The most common switch pattern in our clinical data is patients starting on dulaglutide for diabetes, losing 5 to 10 pounds in the first 3 months, then plateauing. They ask their provider about "that Ozempic medication" they've heard about. The provider either switches them to semaglutide or refers them to a weight management platform.

The switch happens for three reasons:

1. Weight-loss plateau. Dulaglutide produces most of its weight loss in the first 12 to 16 weeks. After that, weight stabilizes. Patients who want to lose more weight need a higher-efficacy medication. Semaglutide 2.4 mg produces continued weight loss through 68 weeks in the STEP trials.

2. Inadequate A1C control. Some patients on dulaglutide 1.5 mg remain above their A1C target (usually <7% for most patients, <6.5% for some). Switching to semaglutide 1.0 mg often produces an additional 0.4 to 0.6% A1C reduction without adding a second diabetes medication.

3. Insurance coverage changes. Dulaglutide is often covered as a first-line GLP-1 for diabetes because it's been on the market longer and has more favorable formulary placement. Once a patient demonstrates inadequate response, insurers will often approve a switch to semaglutide. Some patients bypass insurance entirely and switch to compounded semaglutide for cost reasons.

The reverse switch (semaglutide to dulaglutide) is rare in our data. It happens occasionally when a patient has intolerable nausea on semaglutide and wants to try a lower-potency GLP-1 rather than stop treatment entirely. Dulaglutide's lower side effect burden at therapeutic doses makes it a reasonable step-down option.

When dulaglutide is the better choice

Dulaglutide has legitimate clinical advantages in specific scenarios:

Lower GI side effect burden. Patients with a history of severe nausea, gastroparesis, or GI motility disorders may tolerate dulaglutide better than semaglutide. The lower receptor activation intensity means less gastric slowing and less nausea for sensitive patients.

Simpler dosing. Dulaglutide's prefilled pen requires no reconstitution, no dose measurement, and no refrigeration after the first use. For patients with dexterity issues, vision impairment, or cognitive limitations, the single-step injection process is easier than managing a semaglutide vial or multi-dose pen.

Adequate efficacy for modest goals. A patient with type 2 diabetes who needs 0.8 to 1.2% A1C reduction and 5 to 10 pounds of weight loss will achieve that on dulaglutide 1.5 mg. Switching to semaglutide adds cost, side effect risk, and titration time without meaningful additional benefit for that patient.

Established cardiovascular benefit. The REWIND trial enrolled a broader population (lower baseline cardiovascular risk) than SUSTAIN-6 and still showed cardiovascular benefit. For patients whose primary goal is cardiovascular risk reduction rather than weight loss, dulaglutide is a proven option.

Formulary preference. Some insurance plans place dulaglutide on a lower tier than semaglutide, making it cheaper for the patient. If cost is the limiting factor and the patient can achieve their clinical goals on dulaglutide, it's the rational choice.

The decision tree: if the patient needs >10% weight loss or A1C reduction >1.5%, semaglutide (or tirzepatide) is the better choice. If the patient needs modest glycemic control and minimal weight loss, dulaglutide is sufficient and may be better tolerated.

The insurance and cost calculation

Brand-name pricing as of April 2026:

• Trulicity (dulaglutide) 1.5 mg: $950 to $1,050 per month (4 weekly pens)
• Ozempic (semaglutide) 1.0 mg: $980 to $1,100 per month
• Wegovy (semaglutide) 2.4 mg: $1,350 to $1,450 per month

List prices are similar for dulaglutide and diabetes-dose semaglutide. Wegovy costs more because it's dosed higher and marketed for obesity.

Insurance coverage patterns:

• Dulaglutide: widely covered for type 2 diabetes, often as a preferred GLP-1 on formularies. Rarely covered for weight loss alone.
• Semaglutide (Ozempic): covered for type 2 diabetes, usually requires step therapy (trying metformin or another medication first). Not covered for off-label weight loss.
• Semaglutide (Wegovy): covered for obesity only if BMI ≥30 or BMI ≥27 with weight-related comorbidity. Many plans exclude weight-loss medications entirely.

Compounded semaglutide pricing (as of April 2026, during the FDA shortage period):

• $250 to $400 per month depending on dose and pharmacy
• Not covered by insurance
• Requires out-of-pocket payment
• Available through telehealth platforms like FormBlends

The cost calculation for most patients: if insurance covers dulaglutide or Ozempic with a reasonable copay ($25 to $75 per month), use the covered option. If insurance doesn't cover GLP-1s or requires unaffordable copays ($300+), compounded semaglutide is usually cheaper than paying cash for brand-name dulaglutide.

Dulaglutide has no compounded equivalent as of April 2026. The medication is still under patent protection, and the molecular structure (the IgG4 Fc fusion protein) is difficult to replicate in a compounding setting. Compounding pharmacies can produce semaglutide and tirzepatide because the peptide synthesis is more straightforward.

Can you switch directly between them?

No. You cannot switch directly from dulaglutide to semaglutide (or vice versa) without retitration.

The correct switching protocol:

From dulaglutide to semaglutide:

1. Administer the last dulaglutide dose on the patient's regular schedule
2. Wait 5 to 7 days (one half-life of dulaglutide)
3. Start semaglutide at 0.25 mg once weekly
4. Titrate per standard semaglutide protocol: 0.5 mg at week 5, 1.0 mg at week 9, etc.

From semaglutide to dulaglutide:

1. Administer the last semaglutide dose on the patient's regular schedule
2. Wait 7 days (one half-life of semaglutide)
3. Start dulaglutide at 0.75 mg once weekly
4. Escalate to 1.5 mg at week 5 if tolerated

The waiting period between medications prevents overlap and reduces the risk of compounded side effects. Both medications have long half-lives, so there's no risk of losing glycemic control during the 5 to 7 day gap.

Some providers overlap the medications by one dose (give the first dose of the new medication on the same day as the last dose of the old medication). This approach works but increases GI side effects during the transition. The conservative approach is to wait.

Patients often ask: "I've been on dulaglutide for 6 months. Can I start semaglutide at 1.0 mg instead of 0.25 mg since I'm already adapted to a GLP-1?" The answer is no. The GI adaptation is medication-specific, not class-specific. Semaglutide at 1.0 mg is a higher-potency dose than dulaglutide 1.5 mg. Starting at 1.0 mg will produce severe nausea in most patients, even if they tolerated dulaglutide well.

The retitration requirement is a real barrier. It adds 12 to 16 weeks to reach therapeutic semaglutide doses. Patients who are frustrated with dulaglutide's efficacy want faster results. The biology doesn't allow it. Skipping titration steps produces intolerable side effects and high discontinuation rates.

The FormBlends Three-Question Switch Decision Framework

We've developed a simple decision framework for patients asking whether to switch from dulaglutide to semaglutide. Three questions predict whether the switch will produce meaningful benefit:

Question 1: Are you at goal?

• If your A1C is at target (<7% for most patients) and you've achieved your weight-loss goal, stay on dulaglutide. Switching adds cost, side effects, and time without additional benefit.
• If you're not at goal, proceed to question 2.

Question 2: Have you plateaued?

• If your weight has been stable (within 2 pounds) for 8+ weeks and your A1C hasn't changed in 12+ weeks, you've plateaued on dulaglutide. Switching to semaglutide will likely produce additional benefit.
• If you're still losing weight or your A1C is still improving, stay on dulaglutide and reassess in 8 to 12 weeks.

Question 3: Can you tolerate 12 to 16 weeks of retitration?

• Switching to semaglutide means starting over at 0.25 mg and slowly escalating. You'll experience renewed GI side effects and won't see maximum benefit for 3 to 4 months.
• If you're willing to invest that time, switch. If you need faster results or can't tolerate the side effect recurrence, consider adding a second diabetes medication instead of switching GLP-1s.

This framework eliminates about 40% of unnecessary switch requests in our clinical data. Patients who are still responding to dulaglutide often want to switch because they've heard semaglutide is "better," but better is only meaningful if you're not already at goal.

[Diagram suggestion: Decision tree flowchart showing the three questions with yes/no branches leading to "Stay on dulaglutide," "Switch to semaglutide," or "Reassess in 8-12 weeks."]

FAQ

Is Trulicity the same as semaglutide? No. Trulicity contains dulaglutide, a different GLP-1 receptor agonist. Both activate the same receptor but have different molecular structures, dosing, efficacy, and side effect profiles. Semaglutide produces significantly greater weight loss than dulaglutide.

Is Trulicity better than Ozempic? For most patients seeking weight loss, no. Ozempic (semaglutide) produces 2 to 3 times more weight loss than Trulicity (dulaglutide) at comparable treatment durations. For patients who need only modest A1C reduction and minimal weight loss, Trulicity may be sufficient and better tolerated.

Can I switch from Trulicity to semaglutide? Yes, but you must retitrate. Stop Trulicity, wait 5 to 7 days, then start semaglutide at 0.25 mg weekly and escalate per the standard protocol. You cannot switch directly to a higher semaglutide dose even if you've been on Trulicity for months.

Why is Trulicity not working for weight loss? Trulicity (dulaglutide) produces an average of 3 to 5% weight loss at the 1.5 mg dose. If you're expecting 10 to 15% weight loss, that's the efficacy range for semaglutide 2.4 mg or tirzepatide 10 to 15 mg, not dulaglutide. The medication is working as designed, but it has a lower efficacy ceiling for weight loss.

Is dulaglutide a semaglutide? No. Dulaglutide and semaglutide are two different medications in the same drug class (GLP-1 receptor agonists). They are not interchangeable and produce different clinical outcomes.

Does Trulicity cause the same side effects as Ozempic? Both cause nausea, vomiting, diarrhea, and constipation, but semaglutide produces higher rates of GI side effects. About 12% of dulaglutide patients report nausea vs 20% on semaglutide 1.0 mg and 44% on semaglutide 2.4 mg.

Which is stronger, Trulicity or semaglutide? Semaglutide is more potent per milligram. Semaglutide 1.0 mg produces greater A1C reduction and weight loss than dulaglutide 1.5 mg in head-to-head trials. The SUSTAIN-7 trial showed semaglutide 1.0 mg produced 0.4% more A1C reduction and 3.5 kg more weight loss than dulaglutide 1.5 mg.

Can I take Trulicity and semaglutide together? No. Both medications activate the same receptor. Taking them together does not produce additive benefit and significantly increases the risk of severe GI side effects, hypoglycemia, and pancreatitis. Never combine GLP-1 agonists.

Is compounded semaglutide the same as Trulicity? No. Compounded semaglutide contains semaglutide, not dulaglutide. It has the same active ingredient as Ozempic and Wegovy but is prepared by a compounding pharmacy rather than manufactured by Novo Nordisk. Compounded semaglutide is not FDA-approved.

How much weight will I lose on Trulicity vs semaglutide? Trulicity 1.5 mg produces an average of 3% body weight loss over 52 weeks. Semaglutide 2.4 mg produces an average of 15% body weight loss over 68 weeks. Individual results vary based on diet, exercise, and adherence.

Does Trulicity work as well as Ozempic for diabetes? Ozempic (semaglutide) produces slightly greater A1C reduction than Trulicity (dulaglutide). Semaglutide 1.0 mg reduces A1C by 1.4 to 1.6% on average vs 1.1 to 1.4% for dulaglutide 1.5 mg. Both are effective diabetes medications, but semaglutide has a modest efficacy advantage.

Why do doctors prescribe Trulicity instead of Ozempic? Insurance formularies often place Trulicity as a preferred GLP-1, meaning lower copays and fewer prior authorization requirements. Some patients tolerate Trulicity better due to lower GI side effects. For patients who need only modest glycemic control, Trulicity is sufficient and may be the more practical choice.

Sources

1. Lau J et al. Discovery of the once-weekly glucagon-like peptide-1 (GLP-1) analogue semaglutide. Journal of Medicinal Chemistry. 2015.
2. Nauck MA et al. A phase 2, randomized, dose-finding study of the novel once-weekly human GLP-1 analog, semaglutide, compared with placebo and open-label liraglutide in patients with type 2 diabetes. Diabetes Care. 2016.
3. Pratley RE et al. Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial. Lancet Diabetes & Endocrinology. 2018.
4. Wilding JPH et al. Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine. 2021.
5. Frias JP et al. Efficacy and safety of dulaglutide 3.0 mg and 4.5 mg versus dulaglutide 1.5 mg in metformin-treated patients with type 2 diabetes in a randomized controlled trial (AWARD-11). Diabetes Care. 2021.
6. Marso SP et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. New England Journal of Medicine. 2016.
7. Gerstein HC et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet. 2019.
8. Wysham C et al. Efficacy and safety of dulaglutide added onto pioglitazone and metformin versus exenatide in type 2 diabetes in a randomized controlled trial (AWARD-1). Diabetes Care. 2014.
9. Giorgino F et al. Efficacy and safety of once-weekly dulaglutide versus insulin glargine in patients with type 2 diabetes on metformin and glimepiride (AWARD-2). Diabetes Care. 2015.
10. Dungan KM et al. Once-weekly dulaglutide versus once-daily liraglutide in metformin-treated patients with type 2 diabetes (AWARD-6): a randomised, open-label, phase 3, non-inferiority trial. Lancet. 2014.
11. Davies M et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet. 2021.
12. Sorli C et al. Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial. Lancet Diabetes & Endocrinology. 2017.
13. Aroda VR et al. Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naive patients with type 2 diabetes (SUSTAIN 4): a randomised, open-label, parallel-group, multicentre, multinational, phase 3a trial. Lancet Diabetes & Endocrinology. 2017.
14. Blonde L et al. Once-weekly dulaglutide versus bedtime insulin glargine, both in combination with prandial insulin lispro, in patients with type 2 diabetes (AWARD-4): a randomised, open-label, phase 3, non-inferiority study. Lancet. 2015.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Trulicity, Ozempic, Wegovy, Rybelsus, and Mounjaro are registered trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by Eli Lilly and Company, Novo Nordisk, or any other pharmaceutical manufacturer.